Update on infectious complications following lung transplantation

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 3, 2011, Pages 206-209

  Lease, Erika D ^a   Zaas, David W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

bronchiolitis obliterans syndrome; cytomegalovirus; infection prophylaxis; lung transplant; pulmonary fungal infection

Indexed keywords

AMPHOTERICIN; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; LEFLUNOMIDE; VALGANCICLOVIR;

ABSENCE OF SIDE EFFECTS; ANEMIA; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BRONCHIOLITIS OBLITERANS; CANDIDA; CYTOMEGALOVIRUS INFECTION; DIARRHEA; HUMAN; INFECTION RISK; LOW DRUG DOSE; LUNG DISEASE; LUNG INFECTION; LUNG TRANSPLANTATION; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; RECIPIENT; SURVIVAL TIME;

BRONCHIOLITIS OBLITERANS; CANDIDIASIS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PULMONARY ASPERGILLOSIS; RISK FACTORS;

EID: 79953908284     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328344dba5     Document Type: Article

References (13)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh Official Adult Lung and Heart-Lung Transplant Report - 2010. J Heart Lung Transplant 2010; 29:1104-1118.
2. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001; 3:128-137. (Pubitemid 32756695)
3. Zuk DM, Humar A, Weinkauf JG, et al. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90:672-676.
4. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation. Ann Intern Med 2010; 152:761-769. This was a prospective multicenter randomized trial to evaluate extended CMV prophylaxis in lung transplant patients at risk for CMV infection. The study showed a significant decrease in the incidence of CMV disease in patients who received 12 months of oral valganciclovir versus 3 months. There was not found to be an increase in ganciclovir resistance conferred by the UL-97 mutation in the extended prophylaxis group nor were there significant reports of medication intolerance or toxicity.
5. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181:1391-1396. This study showed an increase in the incidence of BOS in lung transplant patients who developed CMV pneumonitis within the first 6 months after transplantation following discontinuation of ganciclovir prophylaxis.
6. Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010; 202:104-108.
7. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010; 90:419-426.
8. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003; 17:113-134. (Pubitemid 36514573)
9. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-1111. Invasive fungal infections are a frequent cause of morbidity and mortality in lung transplant patients and information regarding these infections has been limited. This article provides important information regarding the epidemiology of transplant- associated invasive fungal infections.
10. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
11. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12:220-229.
12. Arthurs SK, Eid AJ, Deziel PJ, et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant 2010; 24:341-348.
13. Weight SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9:1903-1911.